CTOs on the Move

OncoSec Medical

www.oncosec.com

 
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical’s core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s clinical programs currently include three Phase 2 trials targeting metastatic melanoma Merkel cell carcinoma and cutaneous T-cell lymphoma ...
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million
  • www.oncosec.com
  • 4690 Executive Dr Ste 250
    San Diego, CA USA 92121
  • Phone: 855.662.6732

Executives

Name Title Contact Details

Funding

OncoSec Medical raised $67.3M on 06/09/2015
OncoSec Medical raised $15M on 09/04/2018
OncoSec Medical raised $42M on 01/21/2021

Similar Companies

Avista Pharma

Avista Pharma Solutions is a contract development and manufacturing organization (CDMO) formed through the recent, strategic carve-outs of the CMC business of Array BioPharma, Inc. and contract services business of Scynexis, Inc. These two operations, along with the microbiology and analytical testing capabilities of the parent company Accuratus, create a combined business encompassing over 170,000 square feet of laboratory and manufacturing space which is capable of providing pharmaceutical clients with a broad suite of scientifically-differentiated services. These services are provided from a team with demonstrated expertise in process chemistry, analytical chemistry, manufacturing of novel drugs and specialized animal health services.

StageBio

StageBio serves preclinical histology, pathology and specimen archiving clients in the biopharmaceutical, medical device and contract research industries.

DEKA BioSciences

Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.

Bioporto

BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.

Abivax

Abivax is developing therapies that modulate the body`s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body`s natural immune system mechanisms to treat diseases.